Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) have received an average recommendation of “Moderate Buy” from the twenty brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $98.22.
CRSP has been the subject of a number of recent research reports. Morgan Stanley assumed coverage on shares of CRISPR Therapeutics in a report on Tuesday, October 11th. They issued an “underweight” rating and a $37.00 price objective for the company. EF Hutton Acquisition Co. I began coverage on shares of CRISPR Therapeutics in a research note on Thursday, January 5th. They set a “buy” rating and a $75.00 price objective for the company. Credit Suisse Group cut their target price on CRISPR Therapeutics from $90.00 to $78.00 in a research note on Wednesday, November 2nd. Citigroup cut their target price on CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 23rd. Finally, SVB Leerink raised their target price on CRISPR Therapeutics from $75.00 to $76.00 and gave the stock an “outperform” rating in a research note on Monday, November 7th.
Insiders Place Their Bets
In other news, CEO Samarth Kulkarni sold 25,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, December 28th. The shares were sold at an average price of $40.93, for a total transaction of $1,023,250.00. Following the completion of the transaction, the chief executive officer now directly owns 369,111 shares in the company, valued at $15,107,713.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 75,000 shares of company stock worth $3,660,750 over the last three months. Company insiders own 5.30% of the company’s stock.
Hedge Funds Weigh In On CRISPR Therapeutics
CRISPR Therapeutics Stock Performance
Shares of CRSP opened at $55.27 on Friday. The firm has a market cap of $4.33 billion, a price-to-earnings ratio of -6.28 and a beta of 1.66. CRISPR Therapeutics has a fifty-two week low of $38.94 and a fifty-two week high of $86.95. The firm has a 50 day moving average price of $48.67 and a 200-day moving average price of $59.30.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last announced its quarterly earnings data on Tuesday, November 1st. The company reported ($2.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.30) by $0.06. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $3.53 million. CRISPR Therapeutics had a negative net margin of 4,831.79% and a negative return on equity of 31.34%. As a group, equities research analysts predict that CRISPR Therapeutics will post -9.25 earnings per share for the current year.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.